» Articles » PMID: 23613478

Osteosarcoma of the Mobile Spine

Overview
Journal Ann Oncol
Publisher Elsevier
Specialty Oncology
Date 2013 Apr 25
PMID 23613478
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The aims of this analysis were to investigate features and outcome of high-grade osteosarcomas of the mobile spine.

Patients And Methods: Since 1977, 20 Cooperative Osteosarcoma Study Group patients had a diagnosis of high-grade osteosarcomas of the mobile spine and were included in this retrospective analysis of patient-, tumor- and treatment-related variables and outcome.

Results: The median age was 29 years (range 5-58). Most frequent tumor sites were thoracic and lumbar spine. All but three patients had nonmetastatic disease at diagnosis. Treatment included surgery and chemotherapy for all patients, 13 were also irradiated. Eight patients failed to achieve a macroscopically complete surgical remission (five local, one primary metastases, two both), six died, two are alive, both with radiotherapy. Of 12 patients with complete remission at all sites, three had a recurrence (two local, one metastases) and died. The median follow-up of the 11 survivors was 8.7 years (range 3.1-22.3), 5-year overall and event-free survival rates were 60% and 43%. Age <40 years, nonmetastatic disease at diagnosis and complete remission predicted for better overall survival (OS, P < 0.05).

Conclusions: Osteosarcomas of the mobile spine are rare. With complete resection (and potentially radiotherapy) and chemotherapy, prognosis may be comparable with that of appendicular osteosarcomas.

Citing Articles

Primary malignant bone and soft-tissue tumours of the spine and appendicular sacrum.

Schneider E, Tiefenboeck T, Bohler C, Noebauer-Huhmann I, Lang S, Krepler P Bone Jt Open. 2025; 6(2):109-118.

PMID: 39889749 PMC: 11785419. DOI: 10.1302/2633-1462.62.BJO-2024-0169.R1.


Circular RNA hsa_circ_001350 contributes to osteosarcoma progression by regulating microRNA-578/CCR4-NOT transcription complex and subunit 7/Wnt signaling.

Xu R, Ci X, He F, Chen Y Am J Cancer Res. 2023; 13(6):2360-2375.

PMID: 37424831 PMC: 10326583.


Development of a novel vasculogenic mimicry-associated gene signature for the prognostic assessment of osteosarcoma patients.

Yan L, Li R, Li D, Zhu Y, Lv Z, Wang B Clin Transl Oncol. 2023; 25(12):3501-3518.

PMID: 37219824 DOI: 10.1007/s12094-023-03218-1.


Development and Validation of a Prognostic Model for Overall Survival in Patients with Primary Pelvis and Spine Osteosarcoma: A Population-Based Study and External Validation.

Wang D, Liu F, Li B, Xu J, Gong H, Yang M J Clin Med. 2023; 12(7).

PMID: 37048606 PMC: 10095419. DOI: 10.3390/jcm12072521.


Establishment, Maintenance, and Performance of the Cooperative Osteosarcoma Study Group (COSS).

Bielack S, Kager L, Kuhne T, Langer T, Reichardt P, Blattmann C Cancers (Basel). 2023; 15(5).

PMID: 36900310 PMC: 10000534. DOI: 10.3390/cancers15051520.